Gillian McGovern, Editor

Researchers uncover how type 2 innate lymphoid (ILC2) and T helper 2 (Th2) cells in allergic asthma survive toxic environments, revealing potential new therapeutic strategies for treatment.

Although both sex groups showed cognitive decline, women with chronic kidney disease (CKD) had significantly better cognitive scores than men.

Research highlights the critical link between chronic kidney disease (CKD) and uncontrolled gout, emphasizing a need for enhanced awareness and treatment strategies.

The approval was supported by findings from the TRITON3 trial, which enrolled certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Findings from a meta-analysis reveal biosimilars for inflammatory bowel disease (IBD) offer similar efficacy and safety and maintained remission rates as their reference products.

The FDA approves depemokimab-ulaa as a long-acting treatment for severe asthma, enhancing patient care with fewer injections and improved outcomes.

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Research reveals that isatuximab on-body injector shows consistent safety and efficacy across various body weight groups in multiple myeloma treatment.

After 2 initial doses, inebilizumab is administered with only 2 doses a year.

A study reveals that many asthma patients switch biologics due to perceived ineffectiveness, highlighting the need for personalized treatment strategies.

Aflibercept biosimilar QL1207 shows comparable efficacy to the reference drug in treating diabetic macular edema, offering a potentially affordable treatment option for those facing adherence and accessibility issues.

FDA approves gepotidacin as a new oral treatment for uncomplicated gonorrhea, expanding options against resistant sexually transmitted infections.

New research highlights the benefits of adding isatuximab to standard therapy for newly diagnosed multiple myeloma (NDMM), improving patient outcomes and quality of life.

The FDA approved etuvetidigene autotemcel, the first gene therapy for Wiskott-Aldrich syndrome, transforming treatment options for affected patients.

Pharmacists leverage sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve interconnected cardiovascular-kidney-metabolic (CKM) syndrome outcomes through holistic, patient-centered care.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

Continuous glucose monitoring (CGM) via interstitial fluid, sweat, and saliva are less invasive than prior methods.

The FDA approves a new dose of Omlyclo, the first interchangeable biosimilar to Xolair, enhancing treatment options for allergic and inflammatory conditions.

The supplemental new drug application (sNDA) was assigned a PDUFA target action date of July 26, 2026.

The blood test helps patients avoid unnecessary and invasive biopsies.

Infants hospitalized with respiratory syncytial virus (RSV) bronchiolitis who were born to parents with asthma had a significantly higher risk of later developing asthma, the investigators found.

The National Association of Boards of Pharmacy Leader Discusses the New Uniform Multistate Pharmacy Jurisprudence Examination (UMPJE), designed to standardize pharmacy law assessment while supporting multistate licensure, regulatory compliance, and patient safety.

Research funding disruptions at the National Institutes of Health (NIH) impact clinical trials, threatening treatment options for patients and highlighting the critical role of pharmacists in care continuity.

Thunderstorms significantly increase asthma-related emergency visits, highlighting the need for storm-specific preparedness and management strategies for patients.

With this approval, Itvisma has become the first and only gene replacement therapy available for children 2 years and older, teenagers, and adults with SMA.

The 1-year extension period in trials will be discontinued based on the efficacy results observed in the overall study population, said Novo Nordisk.

The legislation is effective on January 1, 2026.

Data show the overall use of sodium-glucose cotransporter 2 (SGLT2) inhibitors among study participants with chronic kidney disease (CKD) was about 14.8%.

FDA approves an 8-mg aflibercept injection for macular edema following retinal vein occlusion (RVO), offering flexible dosing options for improved patient care.